

|   |                                  |                          |
|---|----------------------------------|--------------------------|
| Form PTO-1449<br>U.S. DEPT. OF COMMERCE<br>PATENT AND TRADEMARK OFFICE<br><br>INFORMATION DISCLOSURE STATEMENT<br>BY APPLICANT<br><br>(Use several sheets if necessary) | ATTY. DKT. NO.<br>IAFG-14        | SERIAL NO.<br>07/835,964 |
|   | APPLICANT<br>COATES et al.       |                          |
|   | FILING DATE<br>February 20, 1992 | GROUP<br>1614            |

## U.S. PATENT DOCUMENTS

| Examiner Initial |    | Document Number | Date     | Name  | Class | Subclass | Filing Date |
|------------------|----|-----------------|----------|---|-------|----------|-------------|
| FL               | AA | 5,859,021       | 01/12/99 | Antiviral Combinations <i>Cheng et al.</i>  | 514   | 274      | 02/22/86    |
| ↓                | AB | 5,756,478       | 05/26/98 | Method for Reducing Toxicity of D-Nucleoside Analogs With L-Nucleosides <i>Cheng et al.</i> | 514   | 45       | 03/15/96    |
|                  | AC | 5,627,186       | 05/06/97 | Antiviral Combinations <i>Cheng et al.</i>  | 514   | 274      | 03/28/94    |
|                  | AD | 5,869,461       | 02/09/99 | Reducing Toxicity of L-Nucleoside Analogs With D-Nucleosides <i>Cheng et al.</i>            | 514   | 43       | 03/16/95    |
|                  | AE |                 |          |   |       |          |             |
|                  | AF |                 |          |   |       |          |             |
|                  | AG |                 |          |   |       |          |             |
|                  | AH |                 |          |   |       |          |             |
|                  | AI |                 |          |   |       |          |             |
|                  | AJ |                 |          |   |       |          |             |
|                  | AK |                 |          |   |       |          |             |

## FOREIGN PATENT DOCUMENTS

| Examiner Initial | Document Number | Date | Name | Class | Subclass | Translation |    |
|------------------|-----------------|------|------|-------|----------|-------------|----|
|                  |                 |      |      |       |          | Yes         | No |
|                  | AL              |      |      |       |          |             |    |
|                  | AM              |      |      |       |          |             |    |
|                  | AN              |      |      |       |          |             |    |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

|                         |    |   |  |                              |  |  |  |
|-------------------------|----|---|--|------------------------------|--|--|--|
| FL                      | AU | Beach et al., "Synthesis of Enantiomerically Pure (2'R,5'S)-(-)-1-[Hydroxymethyl]oxathiolan-5-yl]cytosine as a Potent Antiviral Agent against Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV)," <i>J. Org. Chem.</i> 1992, 57, 2217-2219 |  |                              |  |  |  |
| FL                      | AV | Chang et al., "Deoxycytidine Deaminase-resistant Stereoisomer Is the Active Form of (±)-2',3'-Dideoxy-3'-thiacytidine in the Inhibition of Hepatitis B Virus Replication," <i>Journal of Biological Chemistry</i> , July 15, 1992, Vol. 267, No. 20     |  |                              |  |  |  |
| FL                      | AW | Schinazi et al., "Activities of the Four Optical Isomers of 2',3'-Dideoxy-3'-Thiacytidine (BCH-189) against Human Immunodeficiency Virus Type 1 in Human Lymphocytes," <i>Antimicrobial Agents &amp; Chemotherapy</i> , March 1992, Volume 36, No. 3    |  |                              |  |  |  |
| Examiner <i>K. Cass</i> |    |   |  | Date Considered <i>03/00</i> |  |  |  |